Skip to main content
OpenTrials
Completed

NCT Number: NCT03550950

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

The purpose of this study is to assess the safety and tolerability of JNJ-64232025 following single ascending intravenous (IV) study intervention administrations and a single subcutaneous (SC) intervention administration in healthy participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

SGS Life Science Services

Antwerp, 2060, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female of non-childbearing potential (postmenopausal or permanently sterile)
  • Have a body mass index (BMI) between 19 and 30 kilogram per meter square (kg/m^2) (BMI = weight/height^2), and a body weight of 50 to 100 kilogram (kg), inclusive
  • Healthy on the basis of medical history, a physical examination, vital signs, and 12 lead electrocardiogram (ECG) performed at screening
  • Healthy on the basis of clinical laboratory tests performed at screening and Day -1
  • A woman must have a negative highly sensitive serum pregnancy test at screening and a negative urine pregnancy test on Day -1

Exclusion criteria

  • Has history of any clinically significant medical illness or medical disorders the investigator considers should exclude the participant, including (but not limited to), neuromuscular, hematological disease, immune deficiency state, respiratory disease, hepatic or gastrointestinal disease, neurological or psychiatric disease, ophthalmological disorders, neoplastic disease, renal or urinary tract diseases, or dermatological disease
  • Has a disease or disease treatment associated with immune suppression or lymphopenia, these include but are not limited to bone marrow or organ transplantation, lymphoproliferative disorders, T- or B-cell deficiency syndromes, splenectomy, functional asplenism, and chronic granulomatous disease
  • Has a personal history of or conditions associated with thromboembolic events or bleeding disorders, including (but not limited to) myocardial infarction (MI), cerebral vascular accident (CVA)/stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), hemophilia, or menometrorrhagia
  • Has history of allergy or adverse reactions to shellfish, aluminum, aluminum hydroxide keyhole limpet hemocyanin (KLH), tetanus or tetanus toxoid or its excipients
  • Has a known or suspected intolerance or hypersensitivity to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or to any components of the formulation of JNJ-64232025 and its excipients used in this study

Treatment and study plan

JNJ-64232025 IV

Drug

JNJ-64232025 will be administered as IV infusion.

JNJ-64232025 SC

Drug

JNJ-64232025 will be administered as SC injection.

Placebo

Drug

Matching placebo will be administered as IV infusion or SC injection.

Primary outcomes

  1. Number of Participants with Treatment-Emergent Adverse Events (TEAE) by Severity

    Time frame: Up to Day 113

    An adverse event (AE) is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. The severity of the TEAEs will be assessed as mild, moderate, or severe.

  2. Number of Participants with Serious Adverse Events (SAE)

    Time frame: Up to Day 113

    An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  3. Number of Participants with Clinically Significant Changes in Vital Signs

    Time frame: Up to Day 113

    Number of participants with clinically significant changes in the vital signs including temperature, pulse/heart rate, respiratory rate, and blood pressure will be reported.

  4. Number of Participants with ECG Abnormalities

    Time frame: Up to Day 113

    Number of participants with electrocardiogram (ECG) abnormalities will be reported.

  5. Number of Participants with Clinical Laboratory Abnormalities

    Time frame: Up to Day 113

    Number of participants with clinical laboratory abnormalities, including cytomegalovirus (CMV) and Epstein-Barr virus (EBV) viral loads, will be reported.

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) of JNJ-64232025

    Time frame: Up to Day 113

    The Cmax is the maximum observed plasma concentration of JNJ-64232025.

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-64232025

    Time frame: Up to Day 113

    The Tmax is defined as actual sampling time to reach maximum observed plasma concentration of JNJ-64232025.

  3. Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity with Extrapolation of the Terminal Phase (AUC[0-infinity])

    Time frame: Up to Day 113

    The AUC(0-infinity) is the area under the plasma concentration-time curve from time zero to infinite time, calculated as the sum of AUC(0-last) and C(0-last)/lambda(z); wherein AUC(0-last) is area under the plasma concentration-time curve from time zero to last quantifiable time, C(0-last) is the last observed quantifiable concentration, and lambda(z) is elimination rate constant.

  4. Area Under the Plasma Concentration-Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last])

    Time frame: Up to Day 113

    The AUC(0-last) is the area under the plasma concentration-time curve from time zero to last quantifiable time.

  5. Terminal Half-Life (t1/2)

    Time frame: Up to Day 113

    The t1/2 is the time measured for the plasma concentration to decrease by 1 half to its original concentration. It is associated with the terminal slope of the semi logarithmic drug concentration-time curve, and is calculated as 0.693/lambda(z).

  6. Total Systemic Clearance (C/L)

    Time frame: Up to Day 113

    Systemic clearance is a quantitative measure of the rate at which a drug substance is removed from the body. The total systemic clearance after intravenous dose was estimated by dividing the total administered dose by the plasma AUC(0-infinity).

  7. Apparent Total Systemic Clearance After Extravascular Administration (CL/F)

    Time frame: Up to Day 113

    Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. CL/F is the apparent total systemic clearance after extravascular administration.

  8. Volume of Distribution Based on Terminal Phase (Vz)

    Time frame: Up to Day 113

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug.

  9. Apparent Volume of Distribution Based on Terminal Phase After Extravascular Administration (Vz/F)

    Time frame: Up to Day 113

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug. Apparent volume of distribution after subcutaneous dose (Vz/F) is influenced by the fraction absorbed.

  10. Relative SC Bioavailability (F%)

    Time frame: Up to Day 113

    Relative SC bioavailability will be calculated using the following equation: F (%[percent]) = AUC(0-infinity),SC/ mean AUC(0-infinity),IV *100%.

  11. Number of Participants with Anti-JNJ 64232025 Antibodies

    Time frame: Up to Day 113

    Number of participants with anti-JNJ-64232025 antibodies will be assessed.

  12. Number of Participants with Anti-KLH and Anti-Tetanus Antibodies

    Time frame: Up to Day 113

    Number of participants with antibodies to anti-Keyhole Limpet Hemocyanin (KLH) and anti-tetanus will be assessed.

Sponsors and collaborators

Lead sponsor

Janssen Research & Development, LLC

Industry

Registry information

Official study title

A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 11, 2018
Registry last updated
Feb 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.